LETTER TO THE EDITOR

[18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis

I. Gallais Sérézal1,2, S. Ferkal3, L. Lerman4, S. Mulé5, B. Funalot2 and P. Wolkenstein3,6*

Abstract

Schwannomatosis is a rare autosomal dominant genetic syndrome characterized by the presence of multiple schwannomas. The main symptom is neurogenic pain. The diagnosis requires the presence of several schwannomas and whole-body [18F]FDG-PET/MRI might help detect extra schwannomas in patients when the diagnosis is uncertain. Among the 25 patients treated for Schwannomatosis in our tertiary center, three men and two women had had a [18F]FDG-PET/MRI performed, and the number of schwannomas detected by [18F]FDG-PET/MRI outnumbered the number of schwannomas suspected during the clinical examination. The majority of schwannomas exhibited a radiolabeling (median of 66.7%, range 28–93%). Our findings show that [18F]FDG-PET/MRI could prove useful when suspecting schwannomatosis to accelerate diagnosis and offer optimal care to patients.

Keywords: Schwannomatosis, Diagnosis, [18F]FDG-PET, MRI

Schwannomas are benign tumors of the nerve sheaths. Most of them are solitary lesions, but multiple schwannomas develop in genetic disorders like neurofibromatosis type 2 (NF2) and schwannomatosis. Schwannomatosis is an autosomal dominant genetic syndrome characterized by the presence of multiple schwannomas, and less often meningiomas. The main symptom of schwannomatosis is neurogenic pain but other neurological manifestations are possible, such as muscle atrophy and weakness [1, 2]. Transformation into malignant tumors is extremely rare [3].

An optimal evaluation of the number of lesions is capital in the diagnosis of schwannomatosis since it requires the identification of two or more schwannomas [1].

Also, patients must have no evidence of bilateral vestibular schwannomas on magnetic resonance imaging scan (MRI), no first-degree relative with diagnosed NF2, and no known constitutional NF2 mutation. Whole-body imaging has developed in recent years, and both MRI and [18F]FDG Positron emission tomography (PET)-computed tomography (CT) can help detect asymptomatic lesions. Considering that MRI allows better detection of neural tumors than CT [4] and that schwannoma often exerts hypermetabolism on PET-CTs [5, 6], the combination of both [18F]FDG-PET and MRI methods could prove useful in schwannomatosis. Hence, the interest of [18F]FDG-PET/MRI was tested and then reported in several observations of schwannomatosis [7–9]. In 2015, a study evaluating 153 schwannomas in 13 patients performed [18F]FDG-PET/MRI and showed that the average maximum standardized uptake value (SUVmax) of the schwannomas was 6 [10]. This study confirmed that [18F]FDG-PET/MRI did not apply to the discrimination between benign and malignant tumors.

*Correspondence: pierre.wolkenstein@aphp.fr
1 INSERM, Centre D’Investigation Clinique 006, centre de référence des neurofibromatoses, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France
Full list of author information is available at the end of the article
in schwannomatosis as \( ^{18} \text{F} \)FDG-PET hypermetabolism is uncorrelated to a malignant process but suggested that it might help detect extra schwannomas in cases of uncertain diagnosis.

To test this hypothesis, we retrospectively collected data on \( ^{18} \text{F} \)FDG-PET/MRI performed at a single tertiary center in patients with schwannomatosis. \( ^{18} \text{F} \)FDG-PET/MRI are routinely performed by injecting 4.5 MBq/kg of \( ^{18} \text{F} \)FDG one hour before the simultaneous acquisition of the PET and the MRI sequences of the whole body. The acquisition includes the simultaneous acquisition of PET using motion correction and two MR sequences: 3D-T1-Dixon attenuation correction sequences (MRAC) and diffusion-weighted imaging. PET images were reconstructed with and without MR attenuation correction. Secondly, coronal T2-weighted fat-suppressed images were acquired. Both a radiologist and a nuclear radiologist read the images. Statistical analysis was performed with Graphpad prism, using Wilcoxon test to compare the number of schwannoma detected by the different methods. The asterisk * corresponds to a p-value under 0.05.

Of the 25 patients with a confirmed diagnosis of schwannomatosis, three men and two women had had a whole-body \( ^{18} \text{F} \)FDG-PET/MRI (Table 1). The median age was 23 years (range 18–35) and the median delay between the start of symptoms and the diagnosis was 2 years (range 0–14). Two patients had a segmental form. All patients fulfilled the diagnostic criteria of schwannomatosis, had no family history of
neurofibromatosis, and developed at least two histologically-confirmed schwannomas. The median SUV\textsubscript{max} was 2.5 (range 1.7–6.4). In all five patients, the number of schwannomas detected by $[^{18}\text{F}]$FDG-PET/MRI outnumbered the number of schwannomas suspected during the clinical examination (Fig. 1). We could confirm that the majority of schwannomas exhibited a radiolabeling (median percentage of lesions detected for each patient 66.7%, range 28–93%) (Fig. 2). The two imaging modalities appear to be complementary in the work-up of schwannomatosis, as each technique offers the possibility of identifying schwannomas that were not detected by the other imaging modality (Figs. 3, 4).

In conclusion, our findings show that $[^{18}\text{F}]$FDG-PET/MRI could prove useful in accelerating the diagnosis of schwannomatosis and in offering an optimal follow-up to patients. To better investigate the benefit of $[^{18}\text{F}]$FDG-PET/MRI as a diagnostic tool, a prospective evaluation of patients suspected to have schwannomatosis before
they fulfill the diagnosis criteria would be of great interest.

Acknowledgements
Not applicable.

Authors’ contributions
PW and SF designed the study, IGS collected the data and wrote the first draft of the manuscript, BF collected data on the genetic analysis, LL and SM analysed the radiological images. All authors contributed significantly to the manuscript and approved the final manuscript for publication.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Service de Dermatologie, Centre Hospitalo-Universitaire de Besançon, Besançon, France. 2 Département de Génétique, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France. 3 INSERM, Centre D’Investigation Clinique 006, centre de référence des neurofibromatoses, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France. 4 Service de Médecine Nucléaire, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France. 5 Service de Radiologie, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France. 6 Service de Dermatologie, Hôpital Henri-Mondor, Assistance Publique-Hôpital Paris (AP-HP), Créteil, France.

Received: 15 July 2020   Accepted: 6 January 2021
Published online: 28 January 2021

References
1. Dhamija R, Plotkin S, Asthagiri A, Messiaen L, Babovic-Vuksanovic D. Schwannomatosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. Seattle, WA; 1993.
2. Wolkenstein P, Benchikhi H, Zeller J, Wechsler J, Revuz J. Schwannomatosis: a clinical entity distinct from neurofibromatosis type 2. Dermatol. 1997;195(3):226–31. https://doi.org/10.1159/000245948.
3. Merker VL, Espanza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012;17(10):1317–22.
4. Curati WL, Graif M, Kingsley DPE, King T, Scholtz CL, Steiner RE. MRI in acoustic neuroma: a review of 35 patients. Neuroradiology. 1986;28(3):208–14.
5. Cho DH. Retroperitoneal schwannoma misdiagnosed as an ovarian malignancy. BMJ Case Rep. 2018;2018:1–2.
6. Wang SY, Luo DL, Chen G, Liu ET, Wang SX. FDG-PET/CT of intercostal schwannoma. Clin Nucl Med. 2016;41(6):310–2.
7. Chhabra A, Blakely J. Whole-body imaging in schwannomatosis. Neurology. 2011;76(23):2035.
8. Beylergil V, Haque S, Carver A, Bilsky MH, Carrasquillo JA. Schwannomatosis/neurofibromatosis type 2 associated multiple schwannomas visualized on FDG-PET/CT. Rev Española Med Nucl e Imagen Mol (Engl Ed). 2013;32(4):275–8. https://doi.org/10.1016/j.remnine.2013.07.008.
9. Lieber B, Han B, Allen J, Fatterpekar G, Agarwal N, Kazemi N, et al. Utility of positron emission tomography in schwannomatosis. J Clin Neurosci. 2016;30:138–40. https://doi.org/10.1016/j.jocn.2016.01.027.
10. Ahlawat S, Baig A, Blakeley JO, Jacobs MA, Fayad LM. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis. J Magn Reson Imaging. 2016;44(4):794–803.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.